Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:36:11.362Z.
Calculation as of: 2026-10-06T15:36:11.362Z.
Quote observation: 2026-10-06T15:34:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Canton Strategic Holdings Inc
Market Cap
$186.25M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$182.33M
EV/EBIT Ratio
N/A
TTM Avg
25.06x
3Y Avg
25.06x
5Y Avg
25.06x
Market Cap
$180.06M
EV/EBIT Ratio
N/A
TTM Avg
50.33x
3Y Avg
50.33x
5Y Avg
50.33x
Market Cap
$193.67M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.58M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $186.25M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $189.45M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.33M | N/A | 25.06x | 25.06x | 25.06x |
| Journey Medical Corporation (DERM)vs › | $180.06M | N/A | 50.33x | 50.33x | 50.33x |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.19M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $193.67M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $175.51M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $174.58M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | N/A | N/A | N/A | N/A |
| Nkarta, Inc. (NKTX)vs › | $172.78M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
